Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 46

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 46
---
.

(2) Based on Amendment No. 2 to Schedule 13G/A filed January 23, 2024 by BlackRock Inc. According to Amendment No. 2, BlackRock Inc. has sole voting power and sole dispositive power over 13,160,327 shares and 13,303,281 shares, respectively.

(3) Based on Amendment No. 7 to Schedule 13G/A filed April 10, 2024. According to Amendment No. 7, The Vanguard Group has sole dispositive power over 12,062,313 shares, respectively, and has shared voting power and shared dispositive power over 211,103 shares and 341,737 shares, respectively.

(4) Based on Schedule 13G filed November 14, 2024. According to Schedule 13G, Avoro Capital Advisors LLC and Behzad Aghazadeh, who serves as the portfolio manager and controlling person of Avoro Capital Advisors LLC, have sole voting power and sole dispositive power over 8,888,888 and 8,888,888 shares, respectively.

(5) Based on Schedule 13G/A filed October 16, 2024. According to Schedule 13G, State Street Corporation has shared voting power and shared dispositive power over 5,936,957 shares and 6,354,331 shares, respectively.

#### Equity Compensation Plan Information
The following table provides information as of September 30, 2024 with respect to shares of our Common Stock that may be issued under our equity compensation plans.

|                                                                |     | Equity Compensation Plan Information |     |           |     |                                                                        |     |                                                                                                                                     |     |           |
|                                                                |     | Number ofshares to                   
 be issuedupon                        
 exercise ofoutstanding               
 options,warrants                     
 and rights                           |     |           |     | Weightedaverageexercise priceof outstandingoptions,warrants  andrights |     | Number ofsecuritiesremainingavailable forfuture issuanceunder equitycompensationplans (excluding  securitiesreflected incolumn (a)) |     |           |
| Equity compensation plans approved by security holders (1)     |     |                                      |     | 6,600,427 |     |                                                                 $41.75 |     |                                                                                                                                     |     | 4,600,465 |
| Equity compensation plans not approved by security holders (2) |     |                                      |     |   291,401 |     |                                                                 $49.61 |